Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Histone Deacetylase Inhibitors Research
TopicLeading institutions, researchers & key papers
This cluster of papers explores the role of histone deacetylases (HDACs) in regulating cellular functions, gene expression, and epigenetic modifications. It covers the use of HDAC inhibitors in cancer therapy, their impact on neurodegenerative disorders, and their involvement in protein complexes and enzymatic activity.
159
Works
IDs:OpenAlex
How has Histone Deacetylase Inhibitors Research's publication output changed over time?
ScholarIQpublication output · 2006–2020
Output grew0% over the shown period — from 1 works in 2006 to 1 in 2020.
1
2
3
2
1
1
1
1
1
1
2006200720102011201320162017201820192020
What are the most-cited papers on Histone Deacetylase Inhibitors Research?
ScholarIQmost cited works
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard Petrillo, Delong Liu
S46507181. 2010429 CitationsOPEN ACCESS
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael T. Massengill, Mengyu Xie, Chris Massengill, David Noyes, Gary V. Martinez, Roha Afzal, Zhihua Chen, Xiubao Ren, Scott Antonia, Eric B. Haura, Brian Ruffell, Amer A. Beg
Clinical Cancer Research. 2016352 CitationsOPEN ACCESS
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.
Melinda C. Myzak, Philip Tong, Wan‐Mohaiza Dashwood, Roderick H. Dashwood, Emily Ho
PubMed. 2007314 CitationsOPEN ACCESS
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning, Xianping Lu
The Lancet Oncology. 2019271 Citations
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Lucely Cetina, José Luis Aguilar-Ponce, Óscar Arrieta, Aurora González‐Fierro, Alma Chávez‐Blanco, Erik de la Cruz-Hernandez, Maria Fernanda Vieira Cunha Camargo, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, Carlos Pérez‐Plasencia, Lucía Taja‐Chayeb, Talía Wegman-Ostrosky, Alma Luísa Revilla Vázquez, Alfonso Dueñas‐González
Annals of Oncology. 2007253 Citations
Where is Histone Deacetylase Inhibitors Research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Histone Deacetylase Inhibitors Research is open access?
ScholarIQopen access share
87%OPEN ACCESS
Gold
27%
Green
27%
Hybrid
7%
Bronze
27%
Closed
13%
Related on ScholarIQ
A simple method for clinical assay of superoxide dismutase.
Paper
A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression
Paper
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
Paper
Macrophages in Tumor Microenvironments and the Progression of Tumors
Paper
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death
Paper
The role of ubiquitination in tumorigenesis and targeted drug discovery
Paper